TerminatedPhase 1NCT00923234

Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Technische Universität Dresden
Principal Investigator: Uwe Platzbecker, MD
Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus
Intervention: Azacitidine(drug)
Eligibility: 18 years · All sexes
Timeline: 2009 – 2012

Study locations (4)

Medizinische Klinik und Poliklinik I, Uniklinik, Dresden, Germany
Universitätsklinikum Düsseldorf, Klinik für Hämatologie/Onkologie/klinische Immunologie, Düsseldorf, Germany
Klinikum der J.W. Goethe-Universität, Medizinische Klink II, Frankfurt, Germany
Technische Universität München, Klinikum Rechts der Isar, München, Germany

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00923234 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality →

← Back to all trials